Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Stony Brook University medical researcher developing new medication to prevent colon cancer

20.10.2004


A Stony Brook University researcher is testing a new form of aspirin--one that is much more potent than its commercially available counterpart, but with almost none of the side effects--to determine whether it can be used to prevent colon cancer in patients who are prone to the disease.



The study of the new medication--called nitric oxide-donating aspirin, or nitroaspirin--is supported by a $3.2 million grant from the National Cancer Institute. Basil Rigas, M.D., Professor of Medicine and Chief of the Division of Cancer Prevention at Stony Brook’s School of Medicine, will report the findings of his trials on laboratory animals at the third annual International Conference on Frontiers in Cancer Prevention Research today in Seattle. The conference is sponsored by the American Association for Cancer Research.

"Studies in cell culture and animals have shown that this new aspirin is hundreds to thousands of times more potent than traditional aspirin in inhibiting the growth of colon cancer cells and quite effective in preventing the development of colon cancer in laboratory animals," said Dr. Rigas, who will begin human trials of nitroaspirin by the end of this year.


While traditional aspirin has been shown to be effective in clinical trials in preventing certain cancers, it also is associated with significant side effects, including gastrointestinal bleeding, kidney damage, and allergic reactions ranging from mild to fatal. In addition, traditional aspirin is typically effective in preventing cancer in only about 50 per cent of those who take it.

Colon cancer can take many years to develop, but it is frequently not diagnosed in its earliest stages because cancerous lesions in the colon grown slowly and often without symptoms. More than 148,000 new cases of colon cancer are diagnosed in the U.S. each year and more than 56,000 Americans die of the diseases annually, according to the American Cancer Society.

In order to arrive at a more accurate diagnosis in less time, Dr. Rigas and his colleagues are using an advanced imaging technique called magnifying endoscopy to examine the growth of the earliest recognizable lesions, known as aberrant crypt foci, or ACF. The imaging technique will be used to evaluate 240 patients they expect to enroll over the next three years.

Dr. Rigas’ work focuses on the pharmacological prevention of cancers of the colon and the pancreas. His group has made key contributions to our understanding of how aspirin and aspirin-like drugs prevent colon and other cancers. He is now developing the highly promising nitroaspirin for the prevention of colon and pancreatic cancer, being supported by five NIH grants. He also pioneered the application of infrared spectroscopy to biology with emphasis on cancer, and holds several relevant patents. He is the author of over 100 peer-reviewed publications and has co-authored a textbook of Gastroenterology, which was translated into several foreign languages.

Warren Froelich | EurekAlert!
Further information:
http://www.aacr.org

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>